UBS Group Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $385.00

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its target price cut by equities research analysts at UBS Group from $410.00 to $385.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the biotechnology company's stock. UBS Group's price objective suggests a potential upside of 32.34% from the company's previous close.

Other analysts have also issued reports about the stock. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Bank of America lowered their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Finally, JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.15.

United Therapeutics Stock Up 1.2%

UTHR stock traded up $3.56 during trading on Monday, hitting $290.91. 376,992 shares of the company's stock traded hands, compared to its average volume of 445,637. The firm has a market capitalization of $13.12 billion, a P/E ratio of 11.61, a PEG ratio of 6.22 and a beta of 0.57. United Therapeutics has a 1 year low of $266.98 and a 1 year high of $417.82. The business has a fifty day simple moving average of $301.19 and a two-hundred day simple moving average of $324.08.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the company posted $6.17 EPS. On average, equities research analysts predict that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the sale, the chief financial officer directly owned 8,118 shares of the company's stock, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $10,297,208.76. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 91,681 shares of company stock valued at $27,319,919. 10.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Cerity Partners LLC grew its position in United Therapeutics by 30.4% during the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after buying an additional 2,702 shares during the period. Korea Investment CORP boosted its stake in shares of United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after acquiring an additional 2,300 shares in the last quarter. Nepsis Inc. grew its position in shares of United Therapeutics by 6.7% during the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock valued at $18,057,000 after acquiring an additional 3,653 shares during the period. ExodusPoint Capital Management LP purchased a new position in shares of United Therapeutics in the 4th quarter valued at about $1,899,000. Finally, Raymond James Financial Inc. acquired a new position in United Therapeutics in the 4th quarter worth about $18,257,000. Institutional investors and hedge funds own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.